CBS 2019
CBSMD教育中心
中 文

推荐文献

Abstract

Recommended Article

Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes A Combination of Allogeneic Stem Cells Promotes Cardiac Regeneration Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Association Between Living in Food Deserts and Cardiovascular Risk Burden of 30-Day Readmissions After Percutaneous Coronary Intervention in 833,344 Patients in the United States: Predictors, Causes, and Cost Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity Mode of Death in Heart Failure With Preserved Ejection Fraction

Volume 74, Issue 16, October 2019

JOURNAL:J Am Coll Cardiol. Article Link

Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials: JACC Review Topic of the Week

J Gregson, L Sharples, GW Stone et al. Keywords: clinical trials; Cox proportional hazards; nonproportional hazards; statistics; time-to-event outcomes; trial design

ABSTRACT


Most major clinical trials in cardiology report time-to-event outcomes using the Cox proportional hazards model so that a treatment effect is estimated as the hazard ratio between groups, accompanied by its 95% confidence interval and a log-rank p value. But nonproportionality of hazards (non-PH) over time occurs quite often, making alternative analysis strategies appropriate. This review presents real examples of cardiology trials with different types of non-PH: an early treatment effect, a late treatment effect, and a diminishing treatment effect. In such scenarios, the relative merits of a Cox model, an accelerated failure time model, a milestone analysis, and restricted mean survival time are examined. Some post hoc analyses for exploring any specific pattern of non-PH are also presented. Recommendations are made, particularly regarding how to handle non-PH in pre-defined Statistical Analysis Plans, trial publications, and regulatory submissions.